PharmaSeq

Home Company News & Events Press Releases 2012 NIH funds Phase II Tagging of Histopathology Specimens at PharmaSeq

Press Releases

NIH funds Phase II Tagging of Histopathology Specimens at PharmaSeq

National Institutes of Health funds Tagging of Histopathology Specimens at PharmaSeq

Monmouth Junction, NJ, October 10, 2012. PharmaSeq, Inc., announced today that is has received a multi-year Phase II SBIR grant for a project entitled "Tagging of Histopathology Specimens with Light-Activated p-Chips." The grant was awarded by the National Institute of General Medical Sciences of the National Institutes of Health.

The grant, which is a continuation of work performed under an earlier Phase I award, has the goal of improving the method of tagging, tracking, and retrieving tissue samples in the biomedical laboratory. The most common methods for preserving samples use microscope glass slides or tissue cassettes. The Company estimates that billions of units are used annually in these applications. Labeling is currently done by hand or with optical bar codes, which both require a significant amount of time to locate and retrieve samples from collections. PharmaSeq is developing a superior system that is based on its patented p-Chips -- small, light-activated electronic chips that can easily be attached to slides and cassettes. p-Chips are highly resistant to the chemical reagents routinely used in histopathology laboratories. Also, their small size (0.5 mm square) and low cost break the size and cost barriers that have prevented other types of electronic tagging, including RFID, from wide adaptation. When combined with a specially designed reader, the system can be used to search large slide collections to locate a target sample. Each p-Chip contains a unique serial number that can be linked to a specific sample using common database techniques. The goal of the grant is to provide an end-to-end system that will improve efficiency and reliability in biomedical specimen collections.

Dr. Wlodek Mandecki, President of PharmaSeq, Inc., said, "This award underscores the importance of our p-Chips and related products in improving workflow and reducing costs in histopathology laboratories. It also illustrates the versatility of the p-Chip platform. We previously developed and introduced a system for tagging and labeling small animals, and we project that p-Chips will eventually be used in a wide number of applied and research areas of the life sciences."

For further information, please contact Dr. Richard Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100 ext 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852
Find us on the web at: www.pharmaseq.com.

Home Company News & Events Press Releases 2012 NIH funds Phase II Tagging of Histopathology Specimens at PharmaSeq